Exact Sciences shares are trading higher after the company raised its 2024 adjusted EBITDA guidance. Also, the company announced it expects FDA approval for Cologuard Plus in H2 2024.
Portfolio Pulse from Benzinga Newsdesk
Exact Sciences shares rose as the company increased its 2024 adjusted EBITDA guidance and announced expected FDA approval for Cologuard Plus in the second half of 2024.
September 11, 2024 | 3:30 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Exact Sciences shares are trading higher following an increase in 2024 adjusted EBITDA guidance and the announcement of expected FDA approval for Cologuard Plus in H2 2024.
The increase in 2024 adjusted EBITDA guidance suggests improved financial performance, which is positive for investors. Additionally, the expected FDA approval for Cologuard Plus could lead to new revenue streams, further boosting investor confidence.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100